These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 9302748)

  • 1. Evaluation of bivalent live attenuated influenza A vaccines in children 2 months to 3 years of age: safety, immunogenicity and dose-response.
    Gruber WC; Darden PM; Still JG; Lohr J; Reed G; Wright PF
    Vaccine; 1997; 15(12-13):1379-84. PubMed ID: 9302748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of live attenuated influenza vaccines in children 6-18 months of age: safety, immunogenicity, and efficacy. National Institute of Allergy and Infectious Diseases, Vaccine and Treatment Evaluation Program and the Wyeth-Ayerst ca Influenza Vaccine Investigators Group.
    Gruber WC; Belshe RB; King JC; Treanor JJ; Piedra PA; Wright PF; Reed GW; Anderson E; Newman F
    J Infect Dis; 1996 Jun; 173(6):1313-9. PubMed ID: 8648202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study of live recombinant cold-adapted influenza bivalent vaccine of type A for use in children: an epidemiological control trial.
    Alexandrova GI; Budilovsky GN; Koval TA; Polezhaev FI; Garmashova LM; Ghendon YuZ ; Romanova YR; Smorodintsev AA
    Vaccine; 1986 Jun; 4(2):114-8. PubMed ID: 3524050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of live attenuated cold-adapted and avian-human influenza A/Bethesda/85 (H3N2) reassortant virus vaccines in infants and children.
    Steinhoff MC; Halsey NA; Wilson MH; Burns BA; Samorodin RK; Fries LF; Murphy BR; Clements ML
    J Infect Dis; 1990 Aug; 162(2):394-401. PubMed ID: 2197335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of a live-attenuated influenza vaccine blended and filled at two manufacturing facilities.
    Nolan T; Lee MS; Cordova JM; Cho I; Walker RE; August MJ; Larson S; Coelingh KL; Mendelman PM
    Vaccine; 2003 Mar; 21(11-12):1224-31. PubMed ID: 12559802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of monovalent and trivalent live attenuated influenza vaccines in young children.
    Gruber WC; Kirschner K; Tollefson S; Thompson J; Reed G; Edwards KM; Wright PF
    J Infect Dis; 1993 Jul; 168(1):53-60. PubMed ID: 8390548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine.
    Belshe RB; Gruber WC; Mendelman PM; Mehta HB; Mahmood K; Reisinger K; Treanor J; Zangwill K; Hayden FG; Bernstein DI; Kotloff K; King J; Piedra PA; Block SL; Yan L; Wolff M
    J Infect Dis; 2000 Mar; 181(3):1133-7. PubMed ID: 10720541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children.
    Belshe RB; Mendelman PM; Treanor J; King J; Gruber WC; Piedra P; Bernstein DI; Hayden FG; Kotloff K; Zangwill K; Iacuzio D; Wolff M
    N Engl J Med; 1998 May; 338(20):1405-12. PubMed ID: 9580647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunization of infants and young children with live attenuated trivalent cold-recombinant influenza A H1N1, H3N2, and B vaccine.
    Belshe RB; Swierkosz EM; Anderson EL; Newman FK; Nugent SL; Maassab HF
    J Infect Dis; 1992 Apr; 165(4):727-32. PubMed ID: 1552202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies on reactogenicity and immunogenicity of attenuated bivalent cold recombinant influenza type A (CRA) and inactivated trivalent influenza virus (TI) vaccines in infants and young children.
    Piedra PA; Glezen WP; Mbawuike I; Gruber WC; Baxter BD; Boland FJ; Byrd RW; Fan LL; Lewis JK; Rhodes LJ
    Vaccine; 1993; 11(7):718-24. PubMed ID: 8342319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro production of anti-influenza virus antibody after simultaneous administration of H3N2 and H1N1 cold-adapted vaccines in seronegative children.
    Edwards KM; Snyder P; Thompson JM; Johnson PR; Wright PF
    Vaccine; 1986 Mar; 4(1):50-4. PubMed ID: 3962451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of influenza A virus vaccines in seronegative children: live cold-adapted versus inactivated whole virus.
    Feldman S; Wright PF; Webster RG; Roberson PK; Mahoney J; Thompson J; Doolittle M; Lott L; Johnson P; Christoph RC
    J Infect Dis; 1985 Dec; 152(6):1212-8. PubMed ID: 3905983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effective immunization with live attenuated influenza A virus can be achieved in early infancy. Pediatric Care Center.
    Clements ML; Makhene MK; Karron RA; Murphy BR; Steinhoff MC; Subbarao K; Wilson MH; Wright PF
    J Infect Dis; 1996 Jan; 173(1):44-51. PubMed ID: 8537681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease.
    Edwards KM; Dupont WD; Westrich MK; Plummer WD; Palmer PS; Wright PF
    J Infect Dis; 1994 Jan; 169(1):68-76. PubMed ID: 8277200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Safety and high immunogenicity for children 3 to 15 of a mono- and a divaccine from recombinant influenza A/Brazil /11/78 (H1N1) and A/Bangkok/1/79 (H3N2) viruses obtained from a special donor attenuation base--the cold-adapted virus A/Leningrad/134/47/57 (H2N2)].
    Polezhaev FI; Budilovskiĭ GN; Garmashova LM; Romeĭko-Gurko IuR; Egorov AIu
    Vopr Virusol; 1983; 28(6):710-4. PubMed ID: 6670253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of live attenuated and inactivated influenza vaccines in children with cancer.
    Carr S; Allison KJ; Van De Velde LA; Zhang K; English EY; Iverson A; Daw NC; Howard SC; Navid F; Rodriguez-Galindo C; Yang J; Adderson EE; McCullers JA; Flynn PM
    J Infect Dis; 2011 Nov; 204(10):1475-82. PubMed ID: 21949042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of live, attenuated H1N1 and H3N2 cold-adapted and avian-human influenza A reassortant viruses and inactivated virus vaccine in adults.
    Sears SD; Clements ML; Betts RF; Maassab HF; Murphy BR; Snyder MH
    J Infect Dis; 1988 Dec; 158(6):1209-19. PubMed ID: 3198936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multidose, live attenuated, cold-recombinant, trivalent influenza vaccine in infants and young children.
    Swierkosz EM; Newman FK; Anderson EL; Nugent SL; Mills GB; Belshe RB
    J Infect Dis; 1994 May; 169(5):1121-4. PubMed ID: 8169405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of low and high doses of trivalent live cold-adapted influenza vaccine administered intranasally as drops or spray to healthy children.
    King JC; Lagos R; Bernstein DI; Piedra PA; Kotloff K; Bryant M; Cho I; Belshe RB
    J Infect Dis; 1998 May; 177(5):1394-7. PubMed ID: 9593032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The A/Mallard/6750/78 avian-human, but not the A/Ann Arbor/6/60 cold-adapted, influenza A/Kawasaki/86 (H1N1) reassortant virus vaccine retains partial virulence for infants and children.
    Steinhoff MC; Halsey NA; Fries LF; Wilson MH; King J; Burns BA; Samorodin RK; Perkis V; Murphy BR; Clements ML
    J Infect Dis; 1991 May; 163(5):1023-8. PubMed ID: 2019751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.